| 201 | CAPITAL SOUTHWEST CORP | 22 464 | 496,9 k $ | |
| 202 | First Trust Senior Floating Rate Income Fund II | 51 545 | 496,9 k $ | |
| 203 | BlackRock Debt Strategies Fund | 51 502 | 493,9 k $ | |
| 204 | Eaton Vance Senior Income Trust | 98 865 | 493,3 k $ | |
| 205 | GLADSTONE CAPITAL CORP | 28 409 | 492,9 k $ | |
| 206 | EATON VANCE MUNICIPAL INCOME TRUST | 45 894 | 492,4 k $ | |
| 207 | Sixth Street Specialty Lending Inc | 26 629 | 489,4 k $ | |
| 208 | Ultragenyx Pharmaceutical Inc | 23 302 | 488,2 k $ | |
| 209 | MSC Income Fund Inc | 39 921 | 486,2 k $ | |
| 210 | Corvus Pharmaceuticals Inc | 32 579 | 476,6 k $ | |
| 211 | FS Credit Opportunities Corp | 91 877 | 468,6 k $ | |
| 212 | Rezolute Inc | 151 492 | 462,1 k $ | |
| 213 | Tyra Biosciences Inc | 12 049 | 461,5 k $ | |
| 214 | Barings BDC Inc | 55 991 | 460,8 k $ | |
| 215 | CG oncology Inc | 6 660 | 450,7 k $ | |
| 216 | SLR Investment Corp | 31 335 | 448,4 k $ | |
| 217 | WHITEHORSE FINANCE INC | 60 566 | 448,2 k $ | |
| 218 | Oruka Therapeutics Inc | 9 034 | 443,1 k $ | |
| 219 | Allogene Therapeutics Inc | 180 588 | 440,6 k $ | |
| 220 | Kodiak Sciences Inc | 11 451 | 436,5 k $ | |
| 221 | Arcellx Inc | 3 794 | 435,6 k $ | |
| 222 | Ares Capital Corp | 23 885 | 430,4 k $ | |
| 223 | Nuvation Bio Inc | 100 151 | 429,6 k $ | |
| 224 | Tectonic Therapeutic Inc | 13 799 | 426,5 k $ | |
| 225 | LENZ Therapeutics Inc | 46 542 | 425,9 k $ | |
| 226 | Ares Public Funds | 34 335 | 417,5 k $ | |
| 227 | Blackstone Senior Floating Rat | 31 759 | 411,3 k $ | |
| 228 | Spyre Therapeutics Inc | 8 110 | 409,1 k $ | |
| 229 | CENTESSA PHARMACEUTICALS PLC | 10 286 | 408,6 k $ | |
| 230 | Blackrock Income Trust Inc. | 38 229 | 404,1 k $ | |
| 231 | Morgan Stanley Direct Lending Fund | 28 292 | 395 k $ | |
| 232 | Blackstone Strategic Credit 2027 Term Fund | 35 175 | 392,2 k $ | |
| 233 | BLACKROCK LTD DURATION INCOME TRUST | 30 934 | 389,5 k $ | |
| 234 | Intellia Therapeutics Inc | 30 230 | 387,5 k $ | |
| 235 | ADMA Biologics Inc | 42 683 | 384,6 k $ | |
| 236 | OXFORD SQUARE CAPITAL CORP | 213 488 | 377,9 k $ | |
| 237 | ORIC Pharmaceuticals Inc | 29 069 | 368,3 k $ | |
| 238 | Vir Biotechnology Inc | 40 759 | 365,2 k $ | |
| 239 | Edgewise Therapeutics Inc | 11 544 | 363,6 k $ | |
| 240 | Nuveen Churchill Direct Lending Corp | 28 562 | 363,3 k $ | |
| 241 | Nektar Therapeutics | 4 984 | 358,6 k $ | |
| 242 | Vaxcyte Inc | 6 126 | 356 k $ | |
| 243 | Palvella Therapeutics Inc | 2 765 | 344,7 k $ | |
| 244 | TRIPLEPOINT VENTURE GROWTH BDC CORP | 68 513 | 341,9 k $ | |
| 245 | Relay Therapeutics Inc | 33 957 | 337,9 k $ | |
| 246 | AnaptysBio Inc | 6 067 | 336,5 k $ | |
| 247 | Revolution Medicines Inc | 3 454 | 335,9 k $ | |
| 248 | OFS CAPITAL CORP | 92 665 | 329 k $ | |
| 249 | Praxis Precision Medicines Inc | 1 013 | 326,4 k $ | |
| 250 | Cullinan Therapeutics Inc | 22 875 | 325,1 k $ | |
| 251 | Terns Pharmaceuticals Inc | 6 058 | 319,4 k $ | |
| 252 | Capricor Therapeutics Inc | 10 479 | 318,6 k $ | |
| 253 | Celldex Therapeutics Inc | 9 911 | 314,4 k $ | |
| 254 | Liquidia Corp | 8 169 | 308,3 k $ | |
| 255 | Belite Bio Inc | 1 929 | 307,6 k $ | |
| 256 | CytomX Therapeutics Inc | 65 080 | 305,9 k $ | |
| 257 | Immunome Inc | 13 932 | 304,7 k $ | |
| 258 | Annexon Inc | 54 866 | 304 k $ | |
| 259 | Protagonist Therapeutics Inc | 2 860 | 301,4 k $ | |
| 260 | Apogee Therapeutics Inc | 3 538 | 297,8 k $ | |
| 261 | Celcuity Inc | 2 589 | 295,5 k $ | |
| 262 | Summit Therapeutics Inc | 15 519 | 294,2 k $ | |
| 263 | Bicara Therapeutics Inc | 14 755 | 293,5 k $ | |
| 264 | Denali Therapeutics Inc | 15 166 | 291,2 k $ | |
| 265 | Amylyx Pharmaceuticals Inc | 20 815 | 289,3 k $ | |
| 266 | Rocket Pharmaceuticals Inc | 80 438 | 288 k $ | |
| 267 | Precigen Inc | 73 899 | 286 k $ | |
| 268 | Scholar Rock Holding Corp | 5 816 | 285,9 k $ | |
| 269 | Main Street Capital Corp. | 5 380 | 284,9 k $ | |
| 270 | Omeros Corp | 26 865 | 283,7 k $ | |
| 271 | Cytokinetics Inc | 4 303 | 283,6 k $ | |
| 272 | Rapport Therapeutics Inc | 9 007 | 281,8 k $ | |
| 273 | Compass Therapeutics Inc | 52 846 | 279,6 k $ | |
| 274 | Monte Rosa Therapeutics Inc | 16 718 | 275 k $ | |
| 275 | Stoke Therapeutics Inc | 8 418 | 274,1 k $ | |
| 276 | Arcus Biosciences Inc | 12 664 | 273,5 k $ | |
| 277 | MBX Biosciences Inc | 9 131 | 272,6 k $ | |
| 278 | Zymeworks Inc | 10 702 | 268 k $ | |
| 279 | Ironwood Pharmaceuticals Inc | 76 169 | 267,4 k $ | |
| 280 | Ideaya Biosciences Inc | 8 014 | 267 k $ | |
| 281 | Nuvalent Inc | 2 602 | 266,6 k $ | |
| 282 | Neurogene Inc | 13 033 | 262,7 k $ | |
| 283 | Septerna Inc | 10 719 | 257,6 k $ | |
| 284 | ArriVent Biopharma Inc | 11 165 | 257,6 k $ | |
| 285 | Dyne Therapeutics Inc | 14 150 | 256,5 k $ | |
| 286 | Immunovant Inc | 10 320 | 256,3 k $ | |
| 287 | JADE BIOSCIENCES INC | 18 203 | 255,8 k $ | |
| 288 | Sionna Therapeutics Inc | 6 374 | 255,5 k $ | |
| 289 | Kymera Therapeutics Inc | 3 040 | 253,2 k $ | |
| 290 | Cogent Biosciences Inc | 6 476 | 249,3 k $ | |
| 291 | Janux Therapeutics Inc | 17 821 | 247,7 k $ | |
| 292 | BCP INVESTMENT CORP | 32 830 | 246,9 k $ | |
| 293 | Viking Therapeutics Inc | 7 354 | 239,3 k $ | |
| 294 | Beam Therapeutics Inc | 9 966 | 237,5 k $ | |
| 295 | 4D Molecular Therapeutics Inc | 25 154 | 234,2 k $ | |
| 296 | Prime Medicine Inc | 66 508 | 231,4 k $ | |
| 297 | Inhibrx Biosciences Inc | 3 425 | 230,3 k $ | |
| 298 | Arvinas Inc | 21 676 | 229,8 k $ | |
| 299 | AtaiBeckley Inc | 63 563 | 225 k $ | |
| 300 | Compass Pathways plc | 40 457 | 223,7 k $ | |